300529 Stock Overview
Engages in the research, development, production, and sales of blood purification products for hemadsorption industry in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Jafron Biomedical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥30.61 |
| 52 Week High | CN¥39.24 |
| 52 Week Low | CN¥15.88 |
| Beta | 0.36 |
| 11 Month Change | -2.67% |
| 3 Month Change | 19.71% |
| 1 Year Change | 31.04% |
| 33 Year Change | -42.52% |
| 5 Year Change | -26.11% |
| Change since IPO | 31.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300529 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | -7.9% | -5.6% | -6.7% |
| 1Y | 31.0% | -10.2% | 1.9% |
Return vs Industry: 300529 exceeded the CN Medical Equipment industry which returned -7.8% over the past year.
Return vs Market: 300529 exceeded the CN Market which returned 4% over the past year.
Price Volatility
| 300529 volatility | |
|---|---|
| 300529 Average Weekly Movement | 8.9% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.5% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 300529 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300529's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 2,780 | Fan Dong | www.jafroninternational.com |
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption industry in China and internationally. The company offers solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases; HA series hemoperfusion cartridge, BS bilirubin adsorption column and DNA immunoadsorption column, hemoperfusion machine, and blood purification machine; and other products, such as hemodialyzer, hemodialysis concentrate, disinfectants, resin bandages, online hemodialysis powder bag/bucket, and adsorbable suture with needles.
Jafron Biomedical Co.,Ltd. Fundamentals Summary
| 300529 fundamental statistics | |
|---|---|
| Market cap | CN¥23.70b |
| Earnings (TTM) | CN¥804.47m |
| Revenue (TTM) | CN¥2.63b |
29.5x
P/E Ratio9.0x
P/S RatioIs 300529 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300529 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.63b |
| Cost of Revenue | CN¥508.40m |
| Gross Profit | CN¥2.12b |
| Other Expenses | CN¥1.32b |
| Earnings | CN¥804.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.04 |
| Gross Margin | 80.68% |
| Net Profit Margin | 30.56% |
| Debt/Equity Ratio | 49.1% |
How did 300529 perform over the long term?
See historical performance and comparison